Baillie Gifford & Co
SAGE

Baillie Gifford & Co’s Sage Therapeutics SAGE Stock Holding History

Baillie Gifford & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-63,333
Closed -$688K – 293
2024
Q2 		$688K Sell
63,333
-17,483
-22% -$224K ﹤0.01% 261
2024
Q1 		$1.51M Sell
80,816
-3,949
-5% -$91.1K ﹤0.01% 251
2023
Q4 		$1.84M Sell
84,765
-3,742
-4% -$74.2K ﹤0.01% 254
2023
Q3 		$1.82M Sell
88,507
-5,212
-6% -$151K ﹤0.01% 255
2023
Q2 		$4.41M Sell
93,719
-1,326
-1% -$66K ﹤0.01% 244
2023
Q1 		$3.99M Buy
95,045
+160
+0.2% +$6.88K ﹤0.01% 245
2022
Q4 		$3.62M Buy
94,885
+3,490
+4% +$133K ﹤0.01% 250
2022
Q3 		$3.58M Buy
91,395
+2,949
+3% +$114K ﹤0.01% 253
2022
Q2 		$2.86M Sell
88,446
-10,320
-10% -$346K ﹤0.01% 257
2022
Q1 		$3.27M Buy
98,766
+8,394
+9% +$316K ﹤0.01% 261
2021
Q4 		$3.85M Buy
90,372
+4,074
+5% +$171K ﹤0.01% 261
2021
Q3 		$3.82M Buy
86,298
+6,033
+8% +$277K ﹤0.01% 262
2021
Q2 		$4.56M Buy
80,265
+10,516
+15% +$743K ﹤0.01% 259
2021
Q1 		$5.22M Buy
69,749
+36,833
+112% +$3.02M ﹤0.01% 252
2020
Q4 		$2.85M Buy
32,916
+15,886
+93% +$1.17M ﹤0.01% 240
2020
Q3 		$1.04M Buy
17,030
+15,440
+971% +$783K ﹤0.01% 239
2020
Q2 		$66K Buy
1,590
+711
+81% +$25.8K ﹤0.01% 241
2020
Q1 		$25K Buy
879
+389
+79% +$22.5K ﹤0.01% 224
2019
Q4 		$35K Hold
490
– – ﹤0.01% 225
2019
Q3 		$69K Buy
+490
New +$82K ﹤0.01% 221

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Baillie Gifford & Co's SAGE Position: Q3 2024 in Review

Baillie Gifford & Co sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 63,333 shares — an estimated $688K sold.

Baillie Gifford & Co first reported a position in SAGE in Q3 2019 and held it in 20 quarters. The position peaked at $5.22M in Q1 2021. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Baillie Gifford & Co reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 63,333 Sage Therapeutics shares in Q3 2024, an estimated $688K.
  • Baillie Gifford & Co first reported a position in Sage Therapeutics in Q3 2019 and held it in 20 quarters.
  • Baillie Gifford & Co's Sage Therapeutics position peaked at $5.22M in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Baillie Gifford & Co's 13F filing for Q3 2024, filed 5 Nov 2024.